Deals
Carlyle Said to Consider IPO of Nature's Bounty Alongside Sale
- Nutrition, supplements company could seek New York listing
- Buyout firm is working with Goldman Sachs on sale options
This article is for subscribers only.
Carlyle Group LP is weighing an initial public offering of vitamin and supplement firm Nature’s Bounty Co. alongside its ongoing sale process, people with knowledge of the matter said.
The private equity firm, which is working with Goldman Sachs Group Inc. on options for the maker of the MET-Rx protein brand, is considering listing the company in New York, said the people, who asked not to be identified discussing private information. Talks with potential buyers are ongoing and Nature’s Bounty may still be sold, they said.